Moreover, we revealed that the glucose dependence of CD34+ AML cells was strongly and negatively associated with the expression of EV markers detected in adverse-risk AML patients, including CD4, CD14, CD31, CD40, CD44, CD49e, CD142, CD133-1, and CD209. Here, PECAM1 is linked to acute myeloid leukemia.